Oxidative and Antioxidant Indices to HIIT and Aloe Vera Supplementation in Patients With T2DM

April 17, 2024 updated by: Anja Lazić, University of Nis

METRNL Response, Plasma Oxidative and Antioxidant Indices to HIIT and Aloe Vera Supplementation in Patients With Diabetes Type 2

Diabetes is a prevalent metabolic disease that leads to increased blood sugar levels due to insulin shortage or resistance. Type 2 diabetes is often linked to obesity, which can increase insulin resistance. Meteorin-like protein (METRNL) is a new secreted protein that affects insulin sensitivity and has been found to be negatively related to serum glucose levels in people with diabetes.

Oxidative stress in diabetics can stimulate the production of inflammatory mediators, increasing the activity of the antioxidant system. Aloe vera, a widely used plant, has been used for treating diabetes, wound healing, tumors, and inflammatory bowel disease. It has anti-inflammatory, antioxidant, neuroprotective, antidepressant, and memory-enhancing effects.

Exercise can improve diabetic patients' conditions by increasing the expression of GLUT4 protein and skeletal muscle. High-intensity interval training has been shown to increase the expression of the METORIN gene in human subjects and decrease MDA in type 2 diabetic patients. However, no studies have examined the simultaneous effect of exercise and Aloe vera on diabetes indicators.

The present study aims to investigate the response of METRNL and some oxidative and antioxidant plasma indicators to high-intensity interval training and Aloe vera supplementation in type 2 diabetic men. The findings indicate that exercise and consumption of plants with anti-inflammatory and antioxidant properties can be effective in modulating the pathological effects of diabetes and increasing insulin sensitivity.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Amol, Iran, Islamic Republic of
        • Department of Sport Physiology, Faculty of Sport and Physical education, Islamic Azad University of Ayatollah Amoli, Amol, Iran

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male participants who have been diagnosed with T2DM at least 3 months prior to the start of the study according to standard criteria
  • Inactive participants according to the International Physical Activity Questionnaire (IPAQ)
  • Participants receiving stable medical therapy for T2DM, excluding those on exogenous insulin therapy
  • Participants who were free from injuries or chronic health conditions that could limit their ability to safely participate in an intense exercise program were included in the study

Exclusion Criteria:

  • Fasting glucose above 270 mg / dL
  • Exogenous insulin
  • History of diabetic complications (the final stage of proliferative diabetic retinopathy, or subsequent overt nephropathy, diabetic ketoacidosis, or severe diabetic neuropathy)
  • Hereditary glucose and galactose malabsorption

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: High-Intensity Interval Training
Participants in HIIT group underwent 3 sessions per week for 12 weeks. The HIIT protocol (maximum 60 cycles per 20-minute session) includes 8-second fast pedaling (approximately 80% of maximum heart rate (HR max)) followed by slow pedaling (20-30 rpm) for 12 seconds. To facilitate acceleration and limit the stagnation of the bicycle wheel, the selected resistance was very low (almost zero).
The HIIT group underwent intervention with high intensity interval training. The second group was treated only with aloe vera supplementation for 12 weeks. A third group underwent a combination of HIIT and supplementation, while a fourth - CON group kept usual activities during the intervention duratino
Experimental: Aloe Vera supplementation
Participants in Aloe Vera group underwent supplementation with Aloe vera capsule containing 100 mg of Aloe vera gel powder in the morning immediately after waking up and one capsule after dinner.
Aloe Vera group was treated only with aloe vera supplementation for 12 weeks.
Experimental: HIIT + Aloe Vera
Participants in HIIT group underwent 3 sessions per week for 12 weeks. The HIIT protocol (maximum 60 cycles per 20-minute session) includes 8-second fast pedaling (approximately 80% of maximum heart rate (HR max)) followed by slow pedaling (20-30 rpm) for 12 seconds. To facilitate acceleration and limit the stagnation of the bicycle wheel, the selected resistance was very low (almost zero). Additionally, patients underwent supplementation with Aloe Vera capsules in the morning and after the dinner.
The HIIT group underwent intervention with high intensity interval training. The second group was treated only with aloe vera supplementation for 12 weeks. A third group underwent a combination of HIIT and supplementation, while a fourth - CON group kept usual activities during the intervention duratino
Aloe Vera group was treated only with aloe vera supplementation for 12 weeks.
No Intervention: Control group
The control group continued their daily life activities for 12 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
METRNL - Meteorin Like, Glial Cell Differentiation Regulator
Time Frame: Baseline and 12 weeks
Plasma METRNL content was measured using a special kit (Mybiosource company, USA) with a sensitivity of <0.64 ng / ml, range of 1.56-100 ng / ml by ELISA method
Baseline and 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glutathione peroxidase (GPx)
Time Frame: Baseline and 12 weeks
GPx was measured using a special kit (abcam company, USA) through ELISA method.
Baseline and 12 weeks
Serum superoxide dismutase (SOD)
Time Frame: Baseline and and 12 weeks
SOD was measured using a special kit (Abcam company, USA) through ELISA method.
Baseline and and 12 weeks
Total antioxidant blood capacity (TAD)
Time Frame: Baseline and 12 weeks
TAD was measured using a special kit (Abcam company, USA) through ELISA method.
Baseline and 12 weeks
Plasma malondialdehyde (MDA)
Time Frame: Baseline and 12 weeks
MDA was measured using a special kit (Abcam company, USA) through ELISA method.
Baseline and 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Anja Lazić, Prof., Faculty of Sport and Physical Education, University of Niš

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 15, 2022

Primary Completion (Actual)

June 21, 2023

Study Completion (Actual)

February 19, 2024

Study Registration Dates

First Submitted

March 23, 2024

First Submitted That Met QC Criteria

April 17, 2024

First Posted (Actual)

April 22, 2024

Study Record Updates

Last Update Posted (Actual)

April 22, 2024

Last Update Submitted That Met QC Criteria

April 17, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Type 2

Clinical Trials on Exercise

Subscribe